公开(公告)号：US20160318864A1

公开(公告)日：2016-11-03

申请号：US15108000

申请日：2014-12-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki KOIKE ,  Makoto FUSHIMI ,  Jumpei AIDA ,  Shuhei IKEDA ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Hidekazu TOKUHARA

IPC: C07D207/273 ,  C07D403/12 ,  C07D409/12 ,  C07D401/12 ,  C07D403/14 ,  C07D417/14 ,  C07D413/12 ,  C07D471/04 ,  C07D401/14 ,  C07D417/12 ,  C07D405/12

CPC classification number: C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20180079756A1

公开(公告)日：2018-03-22

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Tatsuki KOIKE ,  Jumpei AIDA ,  Makoto FUSHIMI ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Masako MIYAZAKI ,  Hidekazu TOKUHARA ,  Yasushi HATTORI ,  Makoto KAMATA

IPC: C07D498/04 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D498/04 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383 ,  C07D401/06 ,  C07D401/10 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C12N9/99

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20150238506A1

公开(公告)日：2015-08-27

申请号：US14708433

申请日：2015-05-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Junya SHIRAI ,  Tomokazu KUSUMOTO ,  Hiroyuki NAGAMIYA ,  Izumi KAMO

IPC: A61K31/553 ,  A61K31/4353

CPC classification number: A61K31/553 ,  A61B5/04882 ,  A61B5/202 ,  A61B5/205 ,  A61K31/00 ,  A61K31/4353 ,  A61N1/36007 ,  C07D223/16 ,  C07D487/04 ,  C07D498/04 ,  C07D519/00 ,  G01N33/942

Abstract: The present invention relates to a serotonin 5-HT2C receptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof or a prodrug thereof, and a fused heterocyclic compound having a serotonin 5-HT2C receptor activating action and the like.

Abstract translation: 本发明涉及含有下式表示的化合物的5-羟色胺5-HT 2C受体活化剂，其中环A是任选具有取代基的5-或6-元芳族杂环，环B为7-至9-元 其中m和n（m，n）的组合是（1,2），（2,1），（2,2），（3,1），（ 3,2）或（4,1）或其盐或其前药，以及具有5-羟色胺5-HT 2C受体激活作用的稠合杂环化合物等。